Michael Mull, PA
Physician Assistant · Pittsburgh, PANPI 1194225342
Payments from drug & device makers
Across 519 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$1K
- Lilly USA, LLC$1K
- AstraZeneca$762
- Boehringer Ingelheim$605
- Bayer$601
- plus $4K from 25 others
What the payments were for
- Food & beverage$9,759100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 147 | $2,044 |
| Sanofi-aventis U.S. LLC | 49 | $1,082 |
| Lilly USA, LLC | 56 | $1,069 |
| AstraZeneca(2 entities) | 24 | $762 |
| Boehringer Ingelheim | 35 | $605 |
| Bayer | 38 | $601 |
| Amneal Pharmaceuticals LLC | 26 | $528 |
| Dexcom, Inc. | 8 | $523 |
| Amgen | 13 | $379 |
| AbbVie | 21 | $309 |
| Abbott | 21 | $260 |
| BD | 10 | $258 |
| Merck | 15 | $246 |
| Zealand Pharma US, Inc. | 8 | $166 |
| Tandem Diabetes Care, Inc. | 5 | $166 |
| Amarin Pharma, Inc. | 9 | $164 |
| Johnson & Johnson | 8 | $146 |
| Corcept Therapeutics | 4 | $82 |
| Embecta Corp. | 2 | $65 |
| Xeris Pharmaceuticals, Inc. | 4 | $64 |
| Esperion Therapeutics, Inc. | 2 | $52 |
| Novartis | 3 | $50 |
| Arbor Pharmaceuticals, Inc. | 2 | $39 |
| IBSA Pharma Inc. | 2 | $38 |
| Mannkind Corporation | 1 | $18 |
| Vivus LLC | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Insulet Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$241
- DEXCOM G7 GSS (161)$235
- TZIELD$231
- MOUNJARO$229
- DEXCOM G6 TRANSMITTER$138
- DEXCOM STELO GLUCOSE BIOSENSOR$131
- FARXIGA$125
- Wegovy$121
- EVENITY$103
How this compares
$9,803 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 193 | $235,607 |
| TrulicityDulaglutide | 179 | $210,404 |
| MounjaroTirzepatide | 143 | $169,362 |
| JardianceEmpagliflozin | 125 | $143,707 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $91,486 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $54,731 |
| Humalog Kwikpen U-100Insulin Lispro | 106 | $40,140 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 48 | $38,628 |
| RybelsusSemaglutide | 20 | $34,866 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 214 | $33,403 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $22,810 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $21,971 |
| TradjentaLinagliptin | 27 | $21,826 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $19,603 |
| Novolog FlexpenInsulin Aspart | 45 | $16,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,069 | $389,306361 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $2,044 | $284,900229 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $605 | $197,767184 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,082 | $38,62848 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $528 | $12,557236 claims |
| AbbVieSynthroid | $309 | $2,30733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Pittsburgh
- Dorissa BrivchikPittsburgh$81K
- Amanda MacePittsburgh$29K
- Lauren HoffmannPittsburgh$18K
- Margaret BlichaPittsburgh$18K
- Daniel PorterPittsburgh$16K
- Amanda BembicPittsburgh$16K
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
- Melissa FerrariPhiladelphia$223K
- Jason OberdickWexford$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.